DAIKEN MEDICAL CO.,LTD. (7775)

Price history

¥432Latest-20.7%

Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis

Business overview

As a research and development-driven medical device manufacturer, the Company primarily plans, develops, manufactures and sells products related to anesthesia and the prevention of hospital-acquired infections, with a low proportion of sales generated overseas. It operates from locations centered in Izumi, Osaka, and manages its production technology and quality control systems in accordance with EN ISO 13485:2016. The Company operates as a single-segment business with five product categories. Going forward, it views expansion in overseas markets as a strategic growth opportunity and will promote global expansion, supply chain enhancement, and the recruitment and development of human resources.

Recurring subjects

No threads yetThis company's filings have not been read yet. We are adding them progressively.

Companies sharing a theme

Documents

See all timely disclosures See all statutory filings

News

See all news

Key numbersShowing 8 of 20

PER

82.36How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.

PBR

1.8How many times the company's net assets? Around 1x is generally considered a benchmark.

ROE

2.2%Earning power. A figure above 10% is generally considered good.

Dividend yield

0.0%The annual dividend as a percentage of the share price.

Market capitalization

¥14bnShare price × number of shares. The value of the entire company.

Equity ratio

68.6%The proportion of assets funded by money that does not have to be repaid.

Operating margin

8.8%The percentage of revenue remaining from the company’s core business.

Revenue growth (3 years)

1.1%The average annual growth in sales over the past three years.

What to watch next

Launch and sales expansion of クーデックエイミーPCA (a micropump-based drug infusion device), including consideration of overseas expansion

Second half of fiscal 2025 (as stated)Impact HighLikelihood Medium

Launch of the CAN Project (a solution to reduce exposure to anticancer drugs) after its regulatory application in fiscal 2024: scheduled for the second half of fiscal 2026

Second half of fiscal 2026 (as stated)Impact HighLikelihood Low

Progress in strengthening the sales structure for Europe and obtaining MDR certification, which are prerequisites for sales and launch

Impact MediumLikelihood Medium

Improvement in gross profit and margins through supply-chain upgrades, including shorter lead times, optimized inventory, improved processing yields and fixed-cost reductions

From 2026 onward (based on the continuation of these measures)Impact MediumLikelihood Medium

What to watch next

Who owns itTop holders total 54.5%

Listed holders 54.5%Everyone else 45.5%

Yamada Keiichi (山田圭一)19.01%

Yamada Mitsuru (山田満)13.92%

Yamada Masayuki (山田雅之)10.89%

公益財団法人山田満育英会3.48%

Sekiya Keizo (関家圭三)3.31%

大研医器従業員持株会0.93%

寺田恭子0.90%

羽根一徳0.70%

2 other listed holders1.32%

Who owns it
Holder	Ownership (%)
Yamada Keiichi (山田圭一)	19.01
Yamada Mitsuru (山田満)	13.92
Yamada Masayuki (山田雅之)	10.89
公益財団法人山田満育英会	3.48
Sekiya Keizo (関家圭三)	3.31
大研医器従業員持株会	0.93
寺田恭子	0.90
羽根一徳	0.70
2 other listed holders	1.32

This company's documents

Filings

Timely disclosures

Threads